1
|
Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, Chen H, Rothstein R, Wetzel L, Yang C, Chowdhury P, Tsui P, Steiner P, Jallal B, Herbst R, Hollingsworth RE, Tice DA. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response. Mol Cancer Ther 2016; 15:689-701. [PMID: 26880266 DOI: 10.1158/1535-7163.mct-15-0555] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 02/09/2016] [Indexed: 11/16/2022]
Abstract
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and activated in human cancers. HER3 is a compelling cancer target due to its important role in activation of the oncogenic PI3K/AKT pathway. It has also been demonstrated to confer tumor resistance to a variety of cancer therapies, especially targeted drugs against EGFR and HER2. HER3 can be activated by its ligand (heregulin/HRG), which induces HER3 heterodimerization with EGFR, HER2, or other RTKs. Alternatively, HER3 can be activated in a ligand-independent manner through heterodimerization with HER2 in HER2-amplified cells. We developed a fully human mAb against HER3 (KTN3379) that efficiently suppressed HER3 activity in both ligand-dependent and independent settings. Correspondingly, KTN3379 inhibited tumor growth in divergent tumor models driven by either ligand-dependent or independent mechanisms in vitro and in vivo Most intriguingly, while investigating the mechanistic underpinnings of tumor response to KTN3379, we discovered an interesting dichotomy in that PTEN loss, a frequently occurring oncogenic lesion in a broad range of cancer types, substantially blunted the tumor response in HER2-amplified cancer, but not in the ligand-driven cancer. To our knowledge, this represents the first study ascertaining the impact of PTEN loss on the antitumor efficacy of a HER3 mAb. KTN3379 is currently undergoing a phase Ib clinical trial in patients with advanced solid tumors. Our current study may help us optimize patient selection schemes for KTN3379 to maximize its clinical benefits. Mol Cancer Ther; 15(4); 689-701. ©2016 AACR.
Collapse
Affiliation(s)
- Zhan Xiao
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD.
| | - Rosa A Carrasco
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Kevin Schifferli
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Krista Kinneer
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Ravinder Tammali
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Hong Chen
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Ray Rothstein
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Leslie Wetzel
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Chunning Yang
- Antibody Development and Protein Engineering, MedImmune, Inc., Gaithersburg, Maryland
| | - Partha Chowdhury
- Antibody Development and Protein Engineering, MedImmune, Inc., Gaithersburg, Maryland
| | - Ping Tsui
- Antibody Development and Protein Engineering, MedImmune, Inc., Gaithersburg, Maryland
| | - Philipp Steiner
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Bahija Jallal
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | - Ronald Herbst
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| | | | - David A Tice
- Oncology Research, MedImmune, Inc., One MedImmune Way, Gaithersburg, MD
| |
Collapse
|
2
|
Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype. BIOMED RESEARCH INTERNATIONAL 2015; 2015:634865. [PMID: 26601108 PMCID: PMC4639645 DOI: 10.1155/2015/634865] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/18/2015] [Revised: 09/24/2015] [Accepted: 10/04/2015] [Indexed: 12/21/2022]
Abstract
The study of extracellular vesicles (EVs) in cancer progression is a complex and rapidly evolving field. Whole categories of cellular interactions in cancer which were originally presumed to be due solely to soluble secreted molecules have now evolved to include membrane-enclosed extracellular vesicles (EVs), which include both exosomes and shed microvesicles (MVs), and can contain many of the same molecules as those secreted in soluble form but many different molecules as well. EVs released by cancer cells can transfer mRNA, miRNA, and proteins to different recipient cells within the tumor microenvironment, in both an autocrine and paracrine manner, causing a significant impact on signaling pathways, mRNA transcription, and protein expression. The transfer of EVs to target cells, in turn, supports cancer growth, immunosuppression, and metastasis formation. This review focuses exclusively on breast cancer EVs with an emphasis on breast cancer-derived exosomes, keeping in mind that breast cancer-derived EVs share some common physical properties with EVs of other cancers.
Collapse
|
3
|
Choi W, Wolber R, Gerwat W, Mann T, Batzer J, Smuda C, Liu H, Kolbe L, Hearing VJ. The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin. J Cell Sci 2010; 123:3102-11. [PMID: 20736300 DOI: 10.1242/jcs.064774] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Interactions between melanocytes and neighboring cells in the skin are important in regulating skin color in humans. We recently demonstrated that the less pigmented and thicker skin on the palms and soles is regulated by underlying fibroblasts in those areas, specifically via a secreted factor (DKK1) that modulates Wnt signaling. In this study, we tested the hypothesis that dermal fibroblasts regulate the constitutive skin color of individuals ranging from very light to very dark. We used microarray analysis to compare gene expression patterns in fibroblasts derived from lighter skin types compared to darker skin types, with a focus on secreted proteins. We identified a number of genes that differ dramatically in expression and, among the expressed proteins, neuregulin-1, which is secreted by fibroblasts derived from dark skin, effectively increases the pigmentation of melanocytes in tissue culture and in an artificial skin model and regulates their growth, suggesting that it is one of the major factors determining human skin color.
Collapse
Affiliation(s)
- Wonseon Choi
- Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | |
Collapse
|